American Century Companies’s Ovid Therapeutics OVID Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$456K Buy
+169,382
New +$437K ﹤0.01% 2608
2022
Q4
– Sell
-10,071
Closed -$19K – 2608
2022
Q3
$19K Sell
10,071
-27,230
-73% -$57K ﹤0.01% 2425
2022
Q2
$80K Sell
37,301
-19,574
-34% -$47.3K ﹤0.01% 2250
2022
Q1
$179K Buy
56,875
+9,994
+21% +$31.4K ﹤0.01% 2196
2021
Q4
$150K Buy
46,881
+9,030
+24% +$30.9K ﹤0.01% 2218
2021
Q3
$127K Buy
+37,851
New +$138K ﹤0.01% 2223

Other funds holding OVID

American Century Companies's OVID Position: Q2 2026 in Review

American Century Companies opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 169,382 shares worth $456K. The stake represents ﹤0.01% of the portfolio and ranks #2608 among its holdings. This is a return to the name: American Century Companies previously reported a position in OVID as recently as Q3 2022.

American Century Companies first reported a position in OVID in Q3 2021 and has held it in 6 quarters since. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • American Century Companies held 169,382 shares of Ovid Therapeutics worth $456K as of Q2 2026.
  • Ovid Therapeutics was a new American Century Companies position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2608 holding.
  • American Century Companies first reported a position in Ovid Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.